Loading...
XSTO
CLS B
Market cap20mUSD
Dec 05, Last price  
7.51SEK
1D
1.76%
1Q
-31.73%
Jan 2017
-99.62%
IPO
-99.39%
Name

Clinical Laserthermia Systems AB

Chart & Performance

D1W1MN
XSTO:CLS B chart
P/E
P/S
10.26
EPS
Div Yield, %
Shrs. gr., 5y
129.42%
Rev. gr., 5y
67.47%
Revenues
19m
+127.04%
149,999199,997350,484349,99800003,637,457614,4481,808,0001,426,0001,332,0002,245,0006,268,0008,273,00018,783,000
Net income
-48m
L-40.32%
-671,199-1,977,200-4,953,543-6,974,800-12,696,862-18,325,183-17,841,372-16,594,960-26,948,911-21,263,000-32,854,999-43,375,000-57,939,000-63,615,000-70,660,000-79,792,000-47,623,000
CFO
-56m
L-15.05%
-69,299-2,278,091-4,917,994-5,959,696-12,046,075-18,302,855-15,742,905-18,676,887-19,626,742-24,386,339-38,724,000-39,122,000-55,407,000-66,175,000-70,688,889-66,455,000-56,455,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
IPO date
Apr 16, 2009
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT